Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836430 | 0.84 | L3MBTL1 (0.45) | L3MBTL1BUB1BRD4CREBBPNOTUM | |
| SCHEMBL18487086 | 0.84 | L3MBTL1 (0.45) | L3MBTL1BUB1BRD4CREBBPNOTUM | |
| SCHEMBL424580 | 0.84 | L3MBTL1 (0.48) | L3MBTL1BUB1BRD4CREBBPFABP4 | |
| SCHEMBL29507058 | 0.82 | L3MBTL1 (0.44) | L3MBTL1BUB1BRD4CREBBPNOTUM | |
| SCHEMBL30763696 | 0.82 | NOTUM (0.63) | L3MBTL1BUB1BRD4CREBBPNOTUM | |
| SCHEMBL3237691 | 0.82 | L3MBTL1 (0.44) | SCN9AL3MBTL1BUB1BRD4CREBBP | |
| SCHEMBL18788881 | 0.82 | L3MBTL1 (0.44) | L3MBTL1BUB1BRD4CREBBPNOTUM | |
| SCHEMBL29507077 | 0.82 | L3MBTL1 (0.44) | SCN9AL3MBTL1BUB1BRD4CREBBP | |
| SCHEMBL1284244 | 0.82 | L3MBTL1 (0.44) | L3MBTL1BUB1BRD4CREBBPNOTUM | |
| SCHEMBL2878376 | 0.82 | NOTUM (0.63) | L3MBTL1BUB1BRD4CREBBPNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| EP-2953461-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2953462-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2953456-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3013333-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3013333-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-2753325-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9549921-B2 | Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2014121417-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME CORP. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-31 | — | — | US | disclosed |
| WO-2013033971-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-20110015401-A1 | Metal-Catalyzed Carbon-Fluorine Bond Formation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2066628-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008014186-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | SCN9A 2234/4885L3MBTL1 4540/4885BUB1 4157/4885 |
| US-20110015401-A1 | Metal-Catalyzed Carbon-Fluorine Bond Formation | FLI1, VGF, GMFG | SCN9A 3561/4885L3MBTL1 1577/4885BUB1 4789/4885 |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | SCN9A 4644/4885L3MBTL1 3527/4885BUB1 1694/4885 |
| US-20140213571-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, HAVCR2, EIF2AK2 | SCN9A 3482/4885L3MBTL1 4100/4885BUB1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.